News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
- Solid financial situation and strong visibility:
– Cash position of €10 million
– Operations funded until Q2-2023
- Swissmedic approval for new Phase II study starting summer 2022 evaluating temelimab in patients with severe neuropsychiatric post-COVID syndromes
GENEVA–(BUSINESS WIRE)– Regulatory News:
GeNeuro (Euronext Paris: CH0308403085 – GNRO) (Paris: GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), today reported on its 2022 second quarter cash position and issued a business update.
2022 Second-quarter financial information
At June 30, 2022, GeNeuro had €10 million in cash, which include the net proceeds from the May 2022 capital increase and an unsecured €1 million bank loan that was put in place